Literature DB >> 23184571

Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction.

Vincenzo La Mura1, Marcos Pasarín, Cintia Z Meireles, Rosa Miquel, Aina Rodríguez-Vilarrupla, Diana Hide, Jorge Gracia-Sancho, Juan Carlos García-Pagán, Jaime Bosch, Juan G Abraldes.   

Abstract

UNLABELLED: Endothelial dysfunction drives vascular derangement and organ failure associated with sepsis. However, the consequences of sepsis on liver sinusoidal endothelial function are largely unknown. Statins might improve microvascular dysfunction in sepsis. The present study explores liver vascular abnormalities and the effects of statins in a rat model of endotoxemia. For this purpose, lipopolysaccharide (LPS) or saline was given to: (1) rats treated with placebo; (2) rats treated with simvastatin (25 mg/kg, orally), given at 3 and 23 hours after LPS/saline challenge; (3) rats treated with simvastatin (25 mg/kg/24 h, orally) from 3 days before LPS/saline injection. Livers were isolated and perfused and sinusoidal endothelial function was explored by testing the vasodilation of the liver circulation to increasing concentrations of acetylcholine. The phosphorylated endothelial nitric oxide synthase (PeNOS)/endothelial nitric oxide synthase (eNOS) ratio was measured as a marker of eNOS activation. LPS administration induced an increase in baseline portal perfusion pressure and a decrease in vasodilation to acetylcholine (sinusoidal endothelial dysfunction). This was associated with reduced eNOS phosphorylation and liver inflammation. Simvastatin after LPS challenge did not prevent the increase in baseline portal perfusion pressure, but attenuated the development of sinusoidal endothelial dysfunction. Treatment with simvastatin from 3 days before LPS prevented the increase in baseline perfusion pressure and totally normalized the vasodilating response of the liver vasculature to acetylcholine and reduced liver inflammation. Both protocols of treatment restored a physiologic PeNOS/eNOS ratio.
CONCLUSION: LPS administration induces intrahepatic endothelial dysfunction that might be prevented by simvastatin, suggesting that statins might have potential for liver protection during endotoxemia.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23184571     DOI: 10.1002/hep.26127

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

Review 1.  Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.

Authors:  Rebecca G Kim; Rohit Loomba; Larry J Prokop; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2017-05-04       Impact factor: 11.382

Review 2.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

4.  Therapy. Statins and liver disease: from concern to 'wonder' drugs?

Authors:  Jaume Bosch; Xavier Forns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05-12       Impact factor: 46.802

5.  Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.

Authors:  Arpan Mohanty; Janet P Tate; Guadalupe Garcia-Tsao
Journal:  Gastroenterology       Date:  2015-10-17       Impact factor: 22.682

6.  The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease.

Authors:  Misaki Matsumoto; Jia Zhang; Xueqing Zhang; Junjie Liu; Joy X Jiang; Kanji Yamaguchi; Akiyuki Taruno; Masato Katsuyama; Kazumi Iwata; Masakazu Ibi; Wenhao Cui; Kuniharu Matsuno; Yoshinori Marunaka; Yoshito Itoh; Natalie J Torok; Chihiro Yabe-Nishimura
Journal:  Free Radic Biol Med       Date:  2017-12-20       Impact factor: 7.376

Review 7.  Endothelial nitric oxide synthase in the microcirculation.

Authors:  Xiaohong Shu; T C Stevenson Keller; Daniela Begandt; Joshua T Butcher; Lauren Biwer; Alexander S Keller; Linda Columbus; Brant E Isakson
Journal:  Cell Mol Life Sci       Date:  2015-08-25       Impact factor: 9.261

Review 8.  The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis.

Authors:  Carlos Moctezuma-Velázquez; Juan G Abraldes; Aldo J Montano-Loza
Journal:  Curr Treat Options Gastroenterol       Date:  2018-06

Review 9.  Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement.

Authors:  Vincenzo La Mura; Antonio Nicolini; Giulia Tosetti; Massimo Primignani
Journal:  World J Hepatol       Date:  2015-04-08

Review 10.  'Statins in retinal disease'.

Authors:  Ahmed Al-Janabi; Sue Lightman; Oren Tomkins-Netzer
Journal:  Eye (Lond)       Date:  2018-03-20       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.